Business Context and Reporting Period
This Form 8-K Current Report from Syndax Pharmaceuticals, Inc. (SNDX) covers events occurring on May 14 and May 15, 2024. The filing primarily addresses changes to the Board of Directors and the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Compensation: $45,644 for Board service and $8,558 for Science and Technology Committee service for the newly elected director (prorated for 2024).
- Equity Grant: A one-time option to purchase 35,000 shares of common stock, vesting monthly over three years.
Material Changes
The filing reports the following material changes to corporate governance:
- Board Resignation: Briggs W. Morrison, M.D., resigned from the Board of Directors effective immediately on May 14, 2024. The resignation is not due to any disagreement with the Company.
- Board Election: Aleksandra Rizo, M.D., Ph.D., was unanimously elected to the Board on May 15, 2024, to fill the vacancy left by Dr. Morrison. She was appointed to the Science and Technology Committee and designated as a Class III member.
- Annual Meeting Results: All three proposals at the Annual Meeting held on May 15, 2024, were approved by stockholders.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or new risk factors. It confirms that Dr. Morrison's departure was amicable and that Dr. Rizo's appointment involves standard indemnification agreements and compensation policies.
Investor Verification Checklist
- Verify the impact of the Board composition change on the Science and Technology Committee's strategic direction.
- Review the definitive proxy statement filed on April 2, 2024, for detailed context on the executive compensation advisory vote (Proposal 2), which received significant "Against" votes (16.3 million).
- Confirm the vesting schedule and exercise price of the 35,000 share option granted to Dr. Rizo in subsequent filings or the Company's equity plan documents.
- Monitor future filings for any financial updates, as this 8-K contains no operational or financial performance data.